AC
BBOT

Armistice Capital’s BridgeBio Oncology BBOT Stock Holding History

Armistice Capital’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9M Buy
1,328,000
+328,000
+33% +$3.52M 0.21% 83
2025
Q4 		$12.5M Buy
1,000,000
+588,000
+143% +$7.12M 0.15% 92
2025
Q3 		$4.77M Buy
+412,000
New +$4.29M 0.07% 116

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital's BBOT Position: Q1 2026 in Review

Armistice Capital increased its BridgeBio Oncology (BBOT) stake by 33% in Q1 2026, buying an estimated $3.52M and bringing the position to 1,328,000 shares worth $11.9M. The position accounts for 0.21% of the portfolio, ranked #83.

Armistice Capital first reported a position in BBOT in Q3 2025 and has held it in 3 quarters since. The position peaked at $12.5M in Q4 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Armistice Capital held 1,328,000 shares of BridgeBio Oncology worth $11.9M as of Q1 2026.
  • Armistice Capital bought 328,000 BridgeBio Oncology shares in Q1 2026, an estimated $3.52M.
  • BridgeBio Oncology made up 0.21% of Armistice Capital's portfolio in Q1 2026, its #83 holding.
  • Armistice Capital first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 3 quarters since.
  • Armistice Capital's BridgeBio Oncology position peaked at $12.5M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.